These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37931238)

  • 1. Erratum to: EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
    Neuro Oncol; 2023 Dec; 25(12):2306-2308. PubMed ID: 37931238
    [No Abstract]   [Full Text] [Related]  

  • 2. EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
    Hong B; Yang E; Su D; Ju J; Cui X; Wang Q; Tong F; Zhao J; Yang S; Cheng C; Xin L; Xiao M; Yi K; Zhan Q; Ding Y; Xu H; Cui L; Kang C
    Neuro Oncol; 2024 Jan; 26(1):100-114. PubMed ID: 37651725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of caveolin-1 domain signatures via machine learning and graphlet analysis of single-molecule super-resolution data.
    Khater IM; Meng F; Nabi IR; Hamarneh G
    Bioinformatics; 2019 Sep; 35(18):3468-3475. PubMed ID: 30759191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE2O ubiquitinates PTRF/CAVIN1 and inhibits the secretion of exosome-related PTRF/CAVIN1.
    Cen X; Chen Q; Wang B; Xu H; Wang X; Ling Y; Zhang X; Qin D
    Cell Commun Signal; 2022 Nov; 20(1):191. PubMed ID: 36443833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
    Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C
    Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1.
    Pu W; Nassar ZD; Khabbazi S; Xie N; McMahon KA; Parton RG; Riggins GJ; Harris JM; Parat MO
    J Neurooncol; 2019 Jun; 143(2):207-220. PubMed ID: 30949900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
    Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway.
    Rahman MA; Engelsen AST; Sarowar S; Bindesbøll C; Birkeland E; Goplen D; Lotsberg ML; Knappskog S; Simonsen A; Chekenya M
    Front Cell Dev Biol; 2022; 10():1022191. PubMed ID: 36619857
    [No Abstract]   [Full Text] [Related]  

  • 9. PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9.
    Aung CS; Hill MM; Bastiani M; Parton RG; Parat MO
    Eur J Cell Biol; 2011; 90(2-3):136-42. PubMed ID: 20732728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cavin3 interacts with cavin1 and caveolin1 to increase surface dynamics of caveolae.
    Mohan J; Morén B; Larsson E; Holst MR; Lundmark R
    J Cell Sci; 2015 Mar; 128(5):979-91. PubMed ID: 25588833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.
    Adiyaman SC; V Schnurbein J; De Laffolie J; Hahn A; Siebert R; Wabitsch M; Kamrath C
    J Pediatr Endocrinol Metab; 2022 Jul; 35(7):946-952. PubMed ID: 35405042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-regulation of cell polarization and migration by caveolar proteins PTRF/Cavin-1 and caveolin-1.
    Hill MM; Daud NH; Aung CS; Loo D; Martin S; Murphy S; Black DM; Barry R; Simpson F; Liu L; Pilch PF; Hancock JF; Parat MO; Parton RG
    PLoS One; 2012; 7(8):e43041. PubMed ID: 22912783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis.
    Nassar ZD; Moon H; Duong T; Neo L; Hill MM; Francois M; Parton RG; Parat MO
    Oncotarget; 2013 Oct; 4(10):1844-55. PubMed ID: 24123650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC.
    Zhao Y; Wang Y; Zhao E; Tan Y; Geng B; Kang C; Li X
    Carcinogenesis; 2020 May; 41(3):274-283. PubMed ID: 31605605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function.
    Hill MM; Bastiani M; Luetterforst R; Kirkham M; Kirkham A; Nixon SJ; Walser P; Abankwa D; Oorschot VM; Martin S; Hancock JF; Parton RG
    Cell; 2008 Jan; 132(1):113-24. PubMed ID: 18191225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Yi K; Zhan Q; Wang Q; Tan Y; Fang C; Wang Y; Zhou J; Yang C; Li Y; Kang C
    Neuro Oncol; 2021 Mar; 23(3):387-399. PubMed ID: 33140095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymerase I and transcript release factor transgenic mice show impaired function of hematopoietic stem cells.
    Bai L; Lyu Y; Shi G; Li K; Huang Y; Ma Y; Cong YS; Zhang L; Qin C
    Aging (Albany NY); 2020 Oct; 12(20):20152-20162. PubMed ID: 33087586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression.
    Gould ML; Williams G; Nicholson HD
    Prostate; 2010 Nov; 70(15):1609-21. PubMed ID: 20564315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
    Salaroglio IC; Mujumdar P; Annovazzi L; Kopecka J; Mellai M; Schiffer D; Poulsen SA; Riganti C
    Mol Cancer Ther; 2018 Dec; 17(12):2598-2609. PubMed ID: 30254183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new mutation in the
    Mancioppi V; Daffara T; Romanisio M; Ceccarini G; Pelosini C; Santini F; Bellone S; Mellone S; Baricich A; Rabbone I; Aimaretti G; Akinci B; Giordano M; Prodam F
    Front Endocrinol (Lausanne); 2023; 14():1212729. PubMed ID: 37501786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.